Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China

作     者：Dong-Xu Wang Xu Yang Jian-Zhen Lin Yi Bai Jun-Yu Long Xiao-Bo Yang Samuel Seery Hai-Tao Zhao 

作者机构：Department of Liver SurgeryPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of HumanitiesPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2020年第26卷第30期

页      面：4465-4478页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by the International Science and Technology Cooperation Projects,No.2016YFE0107100 the Capital Special Research Project for Health Development,No.2014-2-4012 the Beijing Natural Science Foundation,No.L172055 and No.7192158 the National Tenthousand Talent Program,the Fundamental Research Funds for the Central Universities,No.3332018032 and the CAMS Innovation Fund for Medical Science(CIFMS),No.2017-I2M-4-003 and No.2018-I2M-3-001 

主　　题：Lenvatinib Real-world study Hepatocellular carcinoma Efficacy Safety Treatment 

摘      要：BACKGROUND Lenvatinib has become an indispensable part of treatment regimens for patients with advanced hepatocellular carcinoma(aHCC).Several recent real-world studies appear to have confirmed this;however,there are etiological *** necessitates further real-world studies of lenvatinib across diverse populations,such as in *** To investigate the efficacy and safety of lenvatinib in a Chinese HCC patient population under real-world *** This is a retrospective and multiregional study involving patients with aHCC receiving lenvatinib *** was assessed using the Response Evaluation Criteria in Solid Tumors version *** characteristics and adverse events(AEs)were recorded throughout the entire *** In total,54 HCC patients treated with lenvatinib monotherapy were included for final *** objective response rate was 22%(n=12)with a progressionfree survival(PFS)of 168 d;however,AEs occurred in 92.8%of *** analysis showed that the Barcelona Clinic Liver Cancer stage[hazard ratio(HR)0.465;95%CI:0.23-0.93;P=0.031],portal vein tumor thrombus(HR 0.38;95%CI:0.15-0.94;P=0.037)and Child-Pugh classifications(HR 0.468;95%CI:and specificity(83.3%)of decreasing serum biomarkers including alphafetoprotein were calculated in order to predict tumor size *** sequencing also provided insights into potential gene mutation signatures related to the effect of *** Our findings confirm previous evidence from the phase III REFLECT *** majority of patients in this Chinese sample were suffering from concomitant hepatitis B virus-related ***,further analysis suggested that baseline characteristics,changes in serum biomarkers and gene sequencing may hold the key for predicting lenvatinib *** large-scale prospective studies that incorporate more basic medical science measures should be conducted.